Section 52
Chapter 51,740

B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen

Mandal, P.K.; Dolai, T.K.; Bagchi, B.; Ghosh, M.K.; Bose, S.; Bhattacharyya, M.

Indian Journal of Pediatrics 81(10): 1092-1094


ISSN/ISBN: 0973-7693
PMID: 24562617
DOI: 10.1007/s12098-013-1336-9
Accession: 051739418

Download citation:  

Non-Hodgkin lymphoma associated with pregnancy is rare. Rituximab based chemotherapy is now considered the standard of care and considered safe for the treatment of diffuse large B-cell lymphoma (DLBCL) during pregnancy but little is known about its safety profile on the fetus. A 32 y primigravida was diagnosed as DLBCL at 20 wk of gestation. She received rituximab containing chemotherapy with successful pregnancy outcome. Though the baby was absolutely healthy, B-cell was totally absent in the cord blood.

PDF emailed within 0-6 h: $19.90